Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Luc Fornecker"'
Autor:
Gandhi Damaj, Steven Le Gouill, Christophe Bonnet, Hervé Ghesquières, David Sibon, Marc André, Emmanuel Itti, Loïc Chartier, Françoise Kraeber-Bodéré, Luc Fornecker, Hervé Tilly, Vincent Ribrag, Franck Morschhauser, Jean-Philippe Jais, Caroline Bodet-Milin, Alina Berriolo-Riedinger, Krimo Bouhabdallah, Philippe Ruminy, Guillaume Cartron, Catherine Thieblemont, Remy Gressin, Reda Bouhabdallah, Corinne Haioun, Lucie Oberic, Thierry Jo Molina, René-Olivier Casasnovas, Pierre Feugier, Josette Brière, Thierry Lamy, Hervé Maisonneuve
Publikováno v:
Blood. 137:2307-2320
Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab. Transplant-eligible patients (18-60 years) with an untreated age-adjusted Intern
Autor:
Alain Delmer, Frederique Orsini, Luc Fornecker, Veronique Leblond, Gilles Salles, Rémi Letestu, Beatrice Mahe, Margot Truchan, Vincent Levy, Fabien Subtil, Brigitte Pegourie, Olivier Tournilhac, Loic Ysebaert, Stéphane Leprêtre, Carmen Aanaei, Magali Le Garff-Tavernier, Thérèse Aurran, Kamel Laribi, Michel Ticchioni, Florence Nguyen-Khac, Valérie Rouille, Marie-Sarah Dilhuydy, Sophie de Guibert, Philippe Carassou, Cécile Tomowiak, Bruno Villemagne, Guillaume Cartron, Anne Banos, Caroline Dartigeas, Florence Cymbalista, Anne-Sophie Michallet, Christelle Portois, Pierre Feugier
Publikováno v:
Blood. 132:1858-1858
Achievement of CR with undetectable minimal residual disease (uMRD) may be associated with a longer survival in CLL, but BCR signaling inhibitors alone seldom allow reaching uMRD. We conducted a multicenter phase II trial aiming at exploring the effi
Autor:
Isabelle Luquet, Sarah Bertoli, Hinrich Gronemeyer, Audrey Sarry, Veronique De Mas, Manon Cassou, Stéphanie Lagarde, Eric Delabesse, Célestine Simand, Pierre Bories, Bastien Cabarrou, Christian Recher, Naïs Prade, Julien Plenecassagnes, Thomas Filleron, Luc Fornecker
Publikováno v:
Blood. 132:2745-2745
Validated therapies for older pts with AML could rely on intensive or low-intensity strategies. Patient selection for these options remains controversial. There is currently no validated biomarker which can been used to guide therapeutic decision. TP
Autor:
Sanne Smits, Julio Finalet-Ferreiro, Joris Vermeesch, Luc Dehaspe, Gregor Verhoef, Olivier Gheysens, Lieselot Buedts, Luc Fornecker, Christiane Copie, Julien Lazarovici, Rene-Olivier Casasnovas, Thomas Tousseyn, Marc André, Peter Vandenberghe
Publikováno v:
Blood. 132:2836-2836
Introduction. For decades, the study of genomic alterations in Hodgkin lymphoma (HL) has been hampered by the low abundance of the malignant Hodgkin Reed-Sternberg (HRS) cells in HL lymph node biopsies. Laser microdissection or flow cytometric cell s
Autor:
Veronique De Mas, Sarah Bertoli, Eric Delabesse, Audrey Sarry, Hinrich Gronemeyer, Luc Fornecker, Pierre Bories, Thomas Filleron, Christian Recher, Stéphanie Lagarde, Naïs Prade, Célestine Simand, Isabelle Luquet, Julien Plenecassagnes, Bastien Cabarrou, Manon Cassou
Publikováno v:
Blood. 132:1467-1467
Hypomethylating agents (HMA) azacitidine (AZA) and decitabine are approved low-intensity frontline therapy for AML pts, but patient selection between intensive versus low-intensity therapy remains mater of debate. To date, description of biomarker of
Autor:
José Fernandes, Thibault Leguay, Norbert Vey, Stéphane Ducassou, Stéphane Leprêtre, Jean-Louis Stephan, Emmanuelle Tavernier, Iman El Hariry, Emmanuel Plouvier, Geneviève Plat, Poiree Maryline, Dominique Plantaz, Cecile Bonin, Anne Auvrignon, Xavier Thomas, Yves Bertrand, Claudine Schmitt, Françoise Mazingue, Alina Ferster, Luc Fornecker, Mathilde Hunault, Victoria Cacheux, Nicolas Blin, Emmanuel Raffoux, André Baruchel, Isabelle Pellier, Virginie Gandemer
Publikováno v:
Blood
Blood, American Society of Hematology, 2015, 126 (23), pp.3723
Blood, 2015, 126 (23), pp.3723
Blood, American Society of Hematology, 2015, 126 (23), pp.3723
Blood, 2015, 126 (23), pp.3723
Background Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies, which can also neutralize asparagin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d64f10f57595ed1f7af723bc9e41573
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01290425
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01290425
Autor:
Yves Bertrand, Françoise Mazingue, Cecile Bonin, Mathilde Hunault, Yann Godfrin, Anne Auvrignon, Claudine Schmitt, Jean-Louis Stephan, Dominique Plantaz, Emmanuel Raffoux, José Fernandes, Nicolas Blin, Geneviève Plat, Thibault Leguay, Maryline Poiree, Emmanuel Plouvier, Alina Ferster, Emmanuelle Tavernier, Xavier Thomas, André Baruchel, Stéphane Ducassou, Luc Fornecker, Victoria Cacheux, Stéphane Leprêtre, Iman El Hariry, Norbert Vey, Isabelle Pellier, Virginie Gandemer
Publikováno v:
Blood
Blood, American Society of Hematology, 2015, 126 (23), pp.3734
Blood, 2015, 126 (23), pp.3734
Blood, American Society of Hematology, 2015, 126 (23), pp.3734
Blood, 2015, 126 (23), pp.3734
Background Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies, which can also neutralize asparagin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7528294cc22b635c512b0684dac89d7
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01290438
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01290438
Autor:
Olivier Chinot, Luc Fornecker, Valérie Touitou, Pierre Soubeyran, Adrian Tempescul, Luc Taillandier, Franck Morschhauser, Roch Houot, Vincent Delwail, Arnaud Jaccard, Philippe Agape, Marie-Pierre Moles, Cécile Chabrot, Nathalie Cassoux, Carole Soussain, Khê Hoang-Xuan, Emmanuel Gyan, Caroline Houillier, Michel Fabbro, Guido Ahle, Annie Brion, Sylvain Choquet, Olivier Casanovas, Remy Gressin, Herve Ghesquieres, Pascal Bourquard, Gandhi Damaj, Fabrice Jardin
Publikováno v:
Blood. 128:926-926
Background The shared knowledge regarding management and outcome of PCNSL patients are usually based on results of clinical phase II studies that include limited series of selected patients, which imperfectly reflect the medical care in "real life".
Autor:
Sandra Malak, Pierre Bories, Sarah Bertoli, Christian Recher, Antoine Nebout, Stéphane Moreau, Luc Fornecker, Célestine Simand, Sébastien Lamy
Publikováno v:
Blood. 128:3576-3576
Frontline therapy for newly diagnosed AML in older adults can be classified as "more" or "less" intensive. Assignment of patients (pts) to intensive chemotherapy (ICT) or low-intensity therapy (LIT) such as hypomethylating agents (HMA), low-dose arac
Autor:
Catherine Thieblemont, Philippe Solal-Celigny, Luc Fornecker, Marie-Christine Béné, Olivier Hermine, Gandhi Damaj, Hacene Zerazhi, Vincent Ribrag, Eric Van Den Neste, Gilles Salles, Remy Gressin, Olivier Tournilhac, Krimo Bouabdallah, Hervé Maisonneuve, Steven Le Gouill, Corinne Haioun, Olivier Casasnovas, Pierre Feugier, Emmanuel Gyan, Anne Moreau, Thierry Lamy, Danielle Canioni, Hervé Tilly, Lucie Oberic
Publikováno v:
Blood. 128:145-145
Mantle cell lymphoma (MCL) accounts for approximately 6% of non-Hodgkin's Lymphoma (NHL) in adults. MCL commonly responds to initial therapy but inevitably patients relapse and response duration decreases from one salvage therapy to the next. Indeed,